Hydrophobic Polysaccharides with Silyl Ether Linkages for Controlled Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Biodegradable polymers used in implantable medical devices often face challenges such as difficulty in forming desired polymeric matrices, biocompatibility issues, inadequate degradation rates, and bulk erosion leading to unintended consequences like embolic events and loss of drug control in drug-release systems.
Innovation Solution
Hydrophobic derivatives of natural biodegradable polysaccharides, specifically α(1→4)glucopyranose polymers with pendent hydrocarbon groups linked via silyl ether segments, which enhance degradation rates by increasing susceptibility to non-enzymatic hydrolysis and enzymatic attack, allowing for controlled release of bioactive agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional biodegradable polymers are used to form polymeric matrices, then the matrices can be formed into desired shapes and sizes, but the degradation rate is insufficient and bulk erosion occurs
Solution Approach 1:
The patent modifies the chemical structure of polysaccharides by introducing silyl ether linkages and hydrocarbon groups, changing the chemical parameters of the polymer to enhance degradation rate while maintaining controlled breakdown
Solution Approach 2:
The patent creates composite structures by combining polysaccharide backbones with silyl ether linkages and hydrocarbon side groups, forming a hybrid material that exhibits both structural integrity and enhanced biodegradability
2Ease of manufacture
If polysaccharides are modified with hydrophobic groups to improve matrix formation, then the polymeric matrices can be formed more effectively, but the biocompatibility may be compromised
Solution Approach 1:
The patent introduces hydrophobic groups at specific locations on the polysaccharide backbone through controlled derivatization, creating local hydrophobic regions that improve matrix formation while maintaining overall biocompatibility through the natural polysaccharide structure
Solution Approach 2:
The patent carefully controls the degree of derivatization and the type of hydrophobic groups introduced, adjusting chemical parameters to optimize both matrix formation properties and biocompatibility
3Ease of operation
If the polymeric matrix is designed to degrade completely in the body, then the requirement for explantation is eliminated, but the degradation products may cause inflammatory responses
Solution Approach 1:
The patent utilizes the natural degradation pathways of polysaccharides and introduces silyl ether linkages that degrade into benign products, converting what could be harmful degradation into beneficial controlled breakdown that eliminates the need for explantation while minimizing inflammation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The enhanced degradation of these polymers facilitates controlled release of bioactive agents and ensures biocompatibility, addressing issues of matrix stability and drug delivery precision, while promoting biodegradability and reducing inflammatory responses.
Implementation Method 1
The enhanced degradation is thought to be caused by increased susceptibility of the linker segments containing silyl ether groups to non-enzymatic hydrolytic attack
Implementation Method 2
The poly-α(1→4)glucopyranose portion can be degraded by amylases
Data Source
AI summary
Hydrophobic α(1→4)glucopyranose polymers with enhanced degradation properties are described. Between the α(1→4)glucopyranose polymeric portion and the hydrophobic portion exists a linker portion having a silyl ether chemistry that facilitates degradation of the polymer. Biodegradable matrices can be formed from these polymers, and the matrices can be used for the preparation of implantable and injectable medical devices wherein the matrix is capable of degrading in vivo at an increased rate. Matrices including and capable of releasing a bioactive agent in vivo are also described.